310 CHAPTER 4.1 Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) B 3. Beta-blocker in combination with verapamil or diltiazem 4 50.0% 1 100% 2 50.0% 0 N/A 1 0% B 13. Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) in severe heart failure characterised by hypotension i.e. systolic BP < 90 mmHg, or concurrent nitrate therapy for angina. 4 25.0% 0 N/A 2 50.0% 0 N/A 2 0.0% C 1. Long-term aspirin at doses greater than 160mg per day 4 50.0% 1 100% 3 33.3% 0 N/A 0 N/A C 2. Aspirin with a past history of peptic ulcer disease without concomitant PPI. 4 0% 2 0% 2 0% 0 N/A 0 N/A E 2. Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73m2 4 75.0% 2 100% 2 50.0% 0 N/A 0 N/A D 8. Anticholinergics/antimuscarinics in patients with delirium or dementia 3 66.7% 0 N/A 0 N/A 1 100% 2 50.0% I 1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, agitation) or narrow-angle glaucoma or chronic prostatism 3 33.3% 0 N/A 1 0% 0 0% 2 50.0% J 3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes 3 33.3% 1 0% 0 N/A 1 100% 1 0%
RkJQdWJsaXNoZXIy MTk4NDMw